Results 21 to 30 of about 119,088 (108)

Pegargiminase Suppresses the Fanconi Anemia Pathway and Promotes Melphalan-Induced DNA Double-Strand Breaks in Uveal Melanoma. [PDF]

Pigment Cell Melanoma Res
ADI‐PEG20 enhances melphalan‐induced DNA DSBs in UM cells. We describe potentiation of DNA DSBs in UM cell lines upon treatment with ADI‐PEG20 and melphalan (92.1 cells with STRIDE by intoDNA). ADI‐PEG20 suppresses multiple members of the FA pathway—a known resistance mechanism for melphalan—providing a rationale for exploring this drug combination in ...
Pavlyk I, Field G, Young M, Carpentier J, Szlosarek EA, O'Keeffe-Brown MR, Crook T, Syed N, Bomalaski JS, Chan PY, Szlosarek PW.   +10 more
europepmc   +2 more sources

Bench-to-Bedside Studies of Arginine Deprivation in Cancer

Molecules, 2023
Arginine is a semi-essential amino acid which becomes wholly essential in many cancers commonly due to the functional loss of Argininosuccinate Synthetase 1 (ASS1).
George C. Field, Iuliia Pavlyk, Peter W. Szlosarek   +2 more
doaj   +1 more source

Supplementary Fig. 7 from Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment

, 2023
Supplemental Figure 7. Gemcitabine and docetaxel increase toxicity to ASS1 KO tumor cells treated with ADI-PEG20 and either chloroquine or imipramine.
Zhixian Hu (16527984), Jeff C. Kremer (16527981), Kooresh I. Shoghi (16527999), John S. Bomalaski (16528008), Adriana Baker (16527990), Carina A. Dehner (16528002), Benjamin A. Garcia (16528011), Leonard C. Rogers (16527978), Caitlyn B. Brashears (15043109), Dong Zhou (16527996), Toshinao Oyama (16528014), Eileen P. White (16528017), Nicole Fettig (16527993), Brian A. Van Tine (10022221), Zongtao Lin (15086911), Alliny C.S. Bastos (16527987), John S.A. Chrisinger (16528005)   +16 more
core   +2 more sources

Insight into the interplay between mitochondria-regulated cell death and energetic metabolism in osteosarcoma

Frontiers in Cell and Developmental Biology, 2022
Osteosarcoma (OS) is a pediatric malignant bone tumor that predominantly affects adolescent and young adults. It has high risk for relapse and over the last four decades no improvement of prognosis was achieved.
Hong Toan Lai, Nataliia Naumova, Antonin Marchais, Antonin Marchais, Nathalie Gaspar, Nathalie Gaspar, Birgit Geoerger, Birgit Geoerger, Catherine Brenner   +8 more
doaj   +1 more source

Metabolic reprogramming in cancer: Mechanisms and therapeutics

MedComm, Volume 4, Issue 2, April 2023., 2023
This article presented the metabolic reprogramming of tumor cells to adapt to their microenvironment distinct from normal cells. And this study reviewed the driving factors of metabolic reprogramming, the specific metabolic pathway changes affected, and the related treatment options, in order to provide some suggestions for future tumor treatment ...
Shiqi Nong, Xiaoyue Han, Yu Xiang, Yuran Qian, Yuhao Wei, Tingyue Zhang, Keyue Tian, Kai Shen, Jing Yang, Xuelei Ma   +9 more
wiley   +1 more source

Collaboration Between RSK-EphA2 and Gas6-Axl RTK Signaling in Arginine Starvation Response That Confers Resistance to EGFR Inhibitors

Translational Oncology, 2020
Many human malignancies require extracellular arginine (Arg) for survival because the key enzyme for de novo Arg biosynthesis, argininosuccinate synthetase 1 (ASS1), is silenced. Recombinant arginine deiminase (ADI-PEG20), which digests extracellular Arg,
Macus Tien Kuo, Yan Long, Wen-Bin Tsai, Ying-Ying Li, Helen H.W. Chen, Lynn G. Feun, Niramol Savaraj   +6 more
doaj   +1 more source

Advanced hepatocellular carcinoma: Impact of systemic treatments on health‐related quality of life and patient‐reported outcomes

Liver Cancer International, Volume 3, Issue 2, Page 90-98, June 2022., 2022
In the past years treatment options for advanced hepatocellular carcinoma (HCC) have thriven. Patient‐reported outcomes (PROs) are often underused in many phase III trials. We performed a systematic review to describe PROs. Abstract In the past years, treatment options for advanced hepatocellular carcinoma (HCC) have thriven.
Giacomo Aimar, Donatella Marino, Clizia Zichi, Teresa Gamba, Andrea Caglio, Francesca De Vita, Elisa Sperti, Massimo Di Maio   +7 more
wiley   +1 more source

Intracellular expression of arginine deiminase activates the mitochondrial apoptosis pathway by inhibiting cytosolic ferritin and inducing chromatin autophagy

BMC Cancer, 2020
Background Based on its low toxicity, arginine starvation therapy has the potential to cure malignant tumors that cannot be treated surgically. The Arginine deiminase (ADI) gene has been identified to be an ideal cancer-suppressor gene.
Qingyuan Feng, Xuzhao Bian, Xuan Liu, Ying Wang, Huiting Zhou, Xiaojing Ma, Chunju Quan, Yi Yao, Zhongliang Zheng   +8 more
doaj   +1 more source

Intracellular arginine-dependent translation sensor reveals the dynamics of arginine starvation response and resistance in ASS1-negative cells

Cancer & Metabolism, 2021
Background Many cancers silence the metabolic enzyme argininosuccinate synthetase 1 (ASS1), the rate-limiting enzyme for arginine biosynthesis within the urea cycle. Consequently, ASS1-negative cells are susceptible to depletion of extracellular arginine
Leonard C. Rogers, Jing Zhou, Adriana Baker, Charles R. Schutt, Prashanta K. Panda, Brian A. Van Tine   +5 more
doaj   +1 more source

Mechanism and application of nonessential amino acid deprivation associated with tumor therapy

MedComm – Future Medicine, Volume 1, Issue 1, June 2022., 2022
Nonessential amino acid (NEAA) deprivation in tumor therapy. Related studies have confirmed in cells and animal models that either increase or decrease of NEAAs can limit the growth of tumor cells. Therefore, here we summarize the possible mechanism and potential applications of NEAAs in diet deprivation therapy, which may provide a direction for the ...
Shiqi Nong, Yuran Qian, Tingyue Zhang, Xueyan Zhou, Yuhao Wei, Xiaomeng Yin, Xuelei Ma   +6 more
wiley   +1 more source